Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

RGEN
Repligen Corp
stock NASDAQ

At Close
Sep 4, 2026 3:59:55 PM EDT
167.51USD-1.238%(-2.10)806,067
0.00Bid   0.00Ask   0.00Spread
Pre-market
Sep 4, 2026 9:25:30 AM EDT
168.40USD-0.713%(-1.21)487
After-hours
Sep 4, 2026 4:00:30 PM EDT
167.60USD+0.054%(+0.09)109,290
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Dec 30, 2021
07:30AM EST  Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 40thAnnual J.P. Morgan Healthcare conference being held January 10-13. Tony J. Hunt, President and Chief Executive Officer, will present on Wednesday, January 12, 2022, at 9:45 a.m. EST.   GlobeNewswire Inc
Nov 12, 2021
07:30AM EST  Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at two upcoming investor conferences.   GlobeNewswire Inc
Nov 5, 2021
07:30AM EDT  Repligen Releases Inaugural Sustainability Report   GlobeNewswire Inc
Oct 29, 2021
05:31AM EDT  SVB Leerink Maintains Outperform on Repligen, Raises Price Target to $325   Benzinga
Oct 28, 2021
08:26AM EDT  The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug   Benzinga
07:53AM EDT  Repligen Raises FY21 Sales Guidance From $625M-$645M To $655M-$665M vs $640.61M Est.   Benzinga
07:50AM EDT  Repligen Q3 Adj. EPS $0.78 Beats $0.64 Estimate, Sales $178.20M Beat $163.97M Estimate   Benzinga
07:30AM EDT  -- Reports record revenue of $178.2 million for the quarter, representing year-over-year growth of 89% and organic growth of 77% -- Raises revenue guidance to $655-$665 million for full year 2021 -- Completes acquisition of affinity ligands innovator Avitide Inc.   GlobeNewswire Inc
04:08AM EDT  Earnings Scheduled For October 28, 2021   Benzinga
Oct 24, 2021
11:45AM EDT  The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More   Benzinga
Oct 14, 2021
11:18AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021   Benzinga
07:30AM EDT  Webcast and Conference Call to Be Held Thursday, October 28, 2021 at 8:30 a.m. EDT   GlobeNewswire Inc
07:04AM EDT  Exane BNP Paribas Initiates Coverage On Repligen with Outperform Rating, Announces Price Target of $330   Benzinga
Sep 30, 2021
07:43AM EDT  The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug   Benzinga
Sep 27, 2021
08:55AM EDT  Craig-Hallum Maintains Buy on Repligen, Raises Price Target to $368   Benzinga
Sep 23, 2021
07:57AM EDT  The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data   Benzinga
Sep 22, 2021
07:45AM EDT  The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs   Benzinga
Sep 21, 2021
08:20AM EDT  The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data   Benzinga
Sep 17, 2021
10:59AM EDT  UPDATE: KeyBanc On Repligen Price Target Raise: Firm Sees Co. 'Quickly Reducing Its Proteins Risk' Given Recent Cytiva Contract Extension & Successful Launches Of Navigo Ligands & Purolite Resins   Benzinga
10:58AM EDT  UPDATE: KeyBanc On Repligen Price Target Raise: Firm Highlights $150M Acquisition Of Avitide For Exposure To Affinity Ligands Production Used In The Purification Of Viral Vectors For Gene Therapies   Benzinga
07:39AM EDT  10 Biggest Price Target Changes For Friday   Benzinga
07:36AM EDT  The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold   Benzinga
04:36AM EDT  Keybanc Maintains Overweight on Repligen, Raises Price Target to $335   Benzinga
Sep 16, 2021
01:08PM EDT  Repligen Reinforces Proteins Business With $150M Avitide Acquisition Deal   Benzinga
07:48AM EDT  The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study   Benzinga
07:44AM EDT  Repligen To Acquire Avitide For $150M   Benzinga
07:41AM EDT  -- Proposed acquisition strengthens Repligens Proteins business   GlobeNewswire Inc
Sep 9, 2021
07:37AM EDT  Repligen And Navigo GmbH Announce Launch Of Industry-First Protein A Ligand for Purification Of pH Sensitive Antibodies   Benzinga
07:30AM EDT  Repligen and Navigo GmbH Announce Launch of   GlobeNewswire Inc
Sep 8, 2021
07:32AM EDT  The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod   Benzinga
Sep 3, 2021
07:31AM EDT  The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself   Benzinga
Sep 2, 2021
08:20AM EDT  The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab   Benzinga
Sep 1, 2021
07:32AM EDT  The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering   Benzinga
Aug 31, 2021
08:15AM EDT  The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical   Benzinga
Aug 27, 2021
07:35AM EDT  The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration   Benzinga
Aug 26, 2021
08:09AM EDT  The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO   Benzinga
Aug 25, 2021
07:30AM EDT  The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug   Benzinga
Aug 24, 2021
08:09AM EDT  The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal   Benzinga
Aug 11, 2021
08:14AM EDT  The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering   Benzinga
Aug 10, 2021
07:55AM EDT  The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts   Benzinga
Aug 6, 2021
07:42AM EDT  The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO   Benzinga
Aug 5, 2021
08:08AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO   Benzinga
Aug 4, 2021
07:52AM EDT  The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings   Benzinga
Aug 3, 2021
07:55AM EDT  The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business   Benzinga
Jul 29, 2021
08:18AM EDT  The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs   Benzinga
Jul 27, 2021
11:13AM EDT  Recap: Repligen Q2 Earnings   Benzinga
11:13AM EDT  Repligen Raises FY21 EPS Guidance From $2.21-$2.28 To $2.71-$2.78 Vs. $2.25 Est., Sales Guidance From $565M-$590M To $625M-$645M Vs. $585.9M Est.   Benzinga
11:13AM EDT  Repligen Q2 EPS $0.79 Beats $0.52 Estimate, Sales $163.00M Beat $144.10M Estimate   Benzinga
04:03AM EDT  Earnings Scheduled For July 27, 2021   Benzinga
Jul 26, 2021
10:37AM EDT  Earnings Outlook For Repligen   Benzinga
Jun 22, 2021
07:20AM EDT  Repligen To Buy Polymem For An Undisclosed Sum   Benzinga
06:39AM EDT  Repligen Announces Agreement To Acquire Polymem   RTTNews
06:30AM EDT  Repligen Corporation Announces Agreement To Acquire Polymem S.A.; Size Of Deal Not Disclosed   Benzinga
06:30AM EDT  Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into an agreement to acquire Toulouse, France based Polymem S.A. (Polymem), a leading industrial expert in the development and manufacture of hollow fiber membranes and modules.   GlobeNewswire Inc
May 25, 2021
07:30AM EDT  Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at two upcoming investor conferences.   GlobeNewswire Inc
May 5, 2021
06:26AM EDT  HC Wainwright & Co. Maintains Buy on Repligen, Raises Price Target to $240   Benzinga
May 4, 2021
10:08AM EDT  Repligen shares were trading higher after the company reported better-than-expected Q1 EPS and sales results. The company raised FY21 EPS and sales guidance above estimates.   Benzinga
08:14AM EDT  Repligen: Q1 Earnings Insights   Benzinga
08:10AM EDT  The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data   Benzinga
07:42AM EDT  Repligen Raises FY21 Sales Guidance From $500M-$525M To $565M-$590M Vs. $513.38M Est., Raises FY21 EPS Guidance From $1.86-$1.94 To $2.21-$2.28 Vs. $1.91 Est.   Benzinga
07:40AM EDT  Repligen Q1 EPS $0.68 Beats $0.42 Estimate, Sales $142.80M Beat $117.01M Estimate   Benzinga
07:30AM EDT  -- Reported revenue was $142.8 million for the quarter, representing year-over-year growth of 88% and organic growth of 69% -- Growth driven by combination of COVID-related demand, base business strength and acquisition revenue   GlobeNewswire Inc
Apr 20, 2021
07:30AM EDT  Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2021 financial results on Tuesday, May 4, 2021. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the three-month reporting period ended March 31, 2021.   GlobeNewswire Inc
Apr 12, 2021
07:45AM EDT  10 Biggest Price Target Changes For Monday   Benzinga
06:36AM EDT  HC Wainwright & Co. Reiterates Buy on Repligen, Raises Price Target to $225   Benzinga
Mar 17, 2021
07:30AM EDT  Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the KeyBanc Life Science and MedTech Investor Forum being held March 23-24. Tony Hunt, President & Chief Executive Officer, will participate in a fireside chat on Wednesday, March 24, at 9:15 a.m. EDT.   GlobeNewswire Inc
Mar 3, 2021
07:30AM EST  Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the Barclays Global Healthcare Conference being held March 9-11. Jon Snodgres, Chief Financial Officer, will participate in a fireside chat on Wednesday, March 10, at 1:50 p.m. EST.   GlobeNewswire Inc
Feb 25, 2021
07:55AM EST  10 Biggest Price Target Changes For Thursday   Benzinga
05:19AM EST  SVB Leerink Maintains Outperform on Repligen, Raises Price Target to $250   Benzinga
Feb 24, 2021
07:48AM EST  Repligen: Q4 Earnings Insights   Benzinga
07:38AM EST  Repligen Sees FY 2021 Adj. EPS $1.86-$1.94 Vs $1.65 Est.   Benzinga
07:37AM EST  Repligen Sees FY 2021 Revs. $500M-$525M Vs $459.53M Est.   Benzinga
07:33AM EST  Repligen Q4 EPS $0.52 Beats $0.31 Estimate, Sales $108.60M Beat $93.88M Estimate   Benzinga
07:30AM EST  -- Reports quarterly revenue of $108.6 million, representing 56% year-over-year growth, and annual revenue of $366.3 million represents 36% year-over-year growth -- Organic revenue growth was 47% for the fourth quarter and 29% for the year 2020   GlobeNewswire Inc
07:30AM EST  The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO   Benzinga
03:35AM EST  Earnings Scheduled For February 24, 2021   Benzinga
Feb 22, 2021
07:30AM EST  Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 10thAnnual SVB Leerink Healthcare conference being held February 22-26. Tony J. Hunt, President and Chief Executive Officer, will participate in a fireside chat on Friday, February 26, at 12:00 p.m. EST.   GlobeNewswire Inc
Feb 11, 2021
03:00PM EST  Webcast and Conference Call to Be Held Wednesday, February 24, 2021 at 8:30 a.m. EST   GlobeNewswire Inc
Feb 8, 2021
07:39AM EST  Repligen, Says Co, Navigo Proteins Announce Launch Of Affinity Resin For Purification Of COVID-19 Vaccines   Benzinga
07:38AM EST  Repligen and Navigo Proteins Announce the Launch of an Affinity   GlobeNewswire Inc
Jan 21, 2021
08:05AM EST  The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping   Benzinga
Jan 20, 2021
07:32AM EST  The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study   Benzinga
Jan 15, 2021
07:57AM EST  The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges   Benzinga
Jan 4, 2021
01:00PM EST  Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 39thAnnual J.P. Morgan Healthcare conference being held January 11-14. Tony J. Hunt, President and Chief Executive Officer, will make a formal presentation on Wednesday, January 13, at 9:10 a.m. EST.   GlobeNewswire Inc
Dec 30, 2020
10:24AM EST  P/E Ratio Insights for Repligen   Benzinga
Dec 10, 2020
04:18PM EST  Repligen Corporation Announces Closing of Public Offering of   GlobeNewswire Inc
Dec 8, 2020
12:21PM EST  EC Mergers & Acquisitions advised ARTeSYN on its Sale to Repligen   PR Newswire
08:04AM EST  The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings   Benzinga
Dec 7, 2020
09:41PM EST  Repligen Corporation Prices Public Offering of Shares of Common Stock   GlobeNewswire Inc
07:36AM EST  Repligen Begins Public Offering Of 1.5 Mln Shares Of Its Common Stock   RTTNews
07:23AM EST  Repligen Announces 1.5M Share Offering   Benzinga
07:22AM EST  Repligen Corporation Announces Proposed Public Offering of Shares   GlobeNewswire Inc
Nov 16, 2020
09:51AM EST  Return On Capital Employed Overview: Repligen   Benzinga
Nov 13, 2020
07:40AM EST  The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations   Benzinga
Nov 8, 2020
03:58PM EST  The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions   Benzinga
12:47PM EST  The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs   Benzinga
Nov 6, 2020
07:47AM EST  The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold   Benzinga
Nov 5, 2020
07:54AM EST  The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping   Benzinga
07:53AM EST  Repligen Raises FY20 EPS Guidance From $1.24-$1.29 To $1.41-$1.45 Vs. $1.28 Est., Sales From $332M-$340M To $348M-$352M Vs. $337.53M Est.   Benzinga
07:51AM EST  Repligen Q3 EPS $0.40 Beats $0.28 Estimate, Sales $94.06M Beat $86.45M Estimate   Benzinga
07:30AM EST  Repligen Reports Third Quarter 2020 Financial Results and Updates   GlobeNewswire Inc
04:34AM EST  Earnings Scheduled For November 5, 2020   Benzinga
Nov 2, 2020
08:59AM EST  Morgan Stanley Maintains Equal-Weight on Rocket Companies, Lowers Price Target to $23   Benzinga
Nov 1, 2020
09:40AM EST  The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings   Benzinga
Oct 27, 2020
04:43PM EDT  Reokigen Announces An Agreement To Acquire Bioprocess Systems Innovator ARTeSYN Biosolutions For Roughly $200M   Benzinga
04:15PM EDT  Repligen Corporation Announces Agreement to Acquire Bioprocess   GlobeNewswire Inc
08:25AM EDT  The Daily Biotech Pulse: Catabasis Halts Duchenne Muscular Dystrophy Study, Lilly's COVID-19 Trial Disappointment, Merck, Pfizer Earnings   Benzinga
Oct 22, 2020
07:30AM EDT  - Webcast and Conference Call to Be Held Thursday, November 5, 2020 at 8:30 a.m. EST -   GlobeNewswire Inc
Oct 1, 2020
06:36AM EDT  Repligen And Navigo Proteins GmbH Announce Development Of Affinity Ligand Targeting Spike Protein   RTTNews
06:36AM EDT  Repligen And Navigo Proteins Announces Their Achievement Of A Key Milestone In Developing An Affinity Resin For The Purification Of Coronavirus Vaccines   Benzinga
06:30AM EDT  Repligen and Navigo Proteins Announce Achievement of Key Milestone   GlobeNewswire Inc
Sep 14, 2020
07:01AM EDT  Repligen and Sanofi Receive Breakthrough Therapy Designation for Dupixent   Benzinga
Aug 24, 2020
08:21AM EDT  10 Biggest Price Target Changes For Monday   Benzinga
06:09AM EDT  HC Wainwright & Co. Maintains Buy on Repligen, Raises Price Target to $168   Benzinga
Jul 30, 2020
07:39AM EDT  Repligen Raises FY20 Adj. EPS From $1.09-$1.14 To $1.24-$1.29 vs $1.13 Est., Raises FY20 Sales Guidance From $309M-$319M To $332M-$340M vs $317.04M Est.   Benzinga
07:37AM EDT  Repligen Q2 Adj. EPS $0.42 Beats $0.27 Estimate, Sales $87.50M Beat $78.38M Estimate   Benzinga
07:30AM EDT  -- Reports record quarterly revenue of $87.5 million -- Overall revenue grew 24% year-over-year, with organic growth of 19% -- Raises revenue guidance to $332-$340 million for full year 2020, representing 18%-21% organic growth -- Completes acquisition of silicone molding and tubing manufacturer Engineered Molding Technology   GlobeNewswire Inc
04:06AM EDT  Earnings Scheduled For July 30, 2020   Benzinga
Jul 15, 2020
07:30AM EDT  Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2020 financial results on Thursday, July 30, 2020. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the three- and six- month reporting periods ended June 30, 2020.   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC